Cancer Drug Parity Act of 2019
- Last Action
- 3/14/2019
Actions
- 2019-03-14Referred to the Subcommittee on Health.
- 2019-03-13Referred to the House Committee on Energy and Commerce.
- 2019-03-13Introduced in House
- 2019-03-13Introduced in House
CRS Summary
As of 2019-03-13 (00)
Cancer Drug Parity Act of 2019
This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.Cosponsors (20)
- Brett Guthrie (R-KY)
- Doris Matsui (D-CA)
- Gus Bilirakis (R-FL)
- Derek Kilmer (D-WA)
- Brian Fitzpatrick (R-PA)
- PETER KING (R-NY)
- JERROLD NADLER (D-NY)
- PETER DEFAZIO (D-OR)
- ALCEE HASTINGS (D-FL)
- Pete Olson (R-TX)
- Debbie Wasserman Schultz (D-FL)
- Will Hurd (R-TX)
- Ami Bera (D-CA)
- Tom Cole (R-OK)
- Ro Khanna (D-CA)
- Michael McCaul (R-TX)
- ELEANOR NORTON (D-DC)
- Robert Latta (R-OH)
- Seth Moulton (D-MA)
- Greg Gianforte (R-MT)
Subjects
- Cancer
- Drug therapy
- Health care costs and insurance
- Health care coverage and access
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.